Advanced glycation end product accumulation: a new enemy to target in chronic kidney disease?

Area of Science:

• Nephrology
• Endocrinology
• Biochemistry

Background:

• Advanced glycation end products (AGEs) are increasingly recognized for their role in chronic disease.
• Their contribution to the progression of chronic kidney disease (CKD) and its complications is a significant area of research.

Purpose of the Study:

• To review recent advancements in understanding the role of AGEs in CKD.
• To highlight novel mechanisms and therapeutic targets for AGEs-induced kidney disease.

Main Methods:

• Literature review of in-vitro, in-vivo, and human studies on AGEs and CKD.
• Analysis of recent research on mechanisms of AGEs-induced end-organ injury.
• Identification of novel therapeutic strategies.

Main Results:

• Over 30 years, AGEs have been linked to CKD progression, particularly diabetic nephropathy.
• While in-vitro and in-vivo studies show detrimental effects, human trials on AGE inhibition are limited.
• Recent research focuses on novel mechanisms of AGEs-induced injury and potential therapeutic targets.

Conclusions:

• Rising CKD prevalence necessitates new therapeutic strategies.
• Understanding AGEs-mediated mechanisms is crucial for developing treatments to delay CKD progression or improve mortality.
• This review focuses on recent studies advancing knowledge on AGEs and potential interventions in kidney disease.